Mirum Pharmaceuticals's total inventories for the quarter that ended in Mar. 2024 was $21.6 Mil. Mirum Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $22.0 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Mirum Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-1.33.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Mirum Pharmaceuticals's Days Inventory for the
three
months ended in Mar. 2024 was 112.38.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Mirum Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.81.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Mirum Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.32.
Mirum Pharmaceuticals Total Inventories Historical Data
The historical data trend for Mirum Pharmaceuticals's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirum Pharmaceuticals Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Mirum Pharmaceuticals (NAS:MIRM) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Mirum Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Mirum Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Mirum Pharmaceuticals Total Inventories Related Terms
Thank you for viewing the detailed overview of Mirum Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Mirum Pharmaceuticals (Mirum Pharmaceuticals) Business Description
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MIRM has been successfully added to your 